CN102596916B - 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物 - Google Patents

3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物 Download PDF

Info

Publication number
CN102596916B
CN102596916B CN201080048756.3A CN201080048756A CN102596916B CN 102596916 B CN102596916 B CN 102596916B CN 201080048756 A CN201080048756 A CN 201080048756A CN 102596916 B CN102596916 B CN 102596916B
Authority
CN
China
Prior art keywords
compound
acid
disease
symptom
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080048756.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102596916A (zh
Inventor
R·艾希霍尔茨
F·布拉斯科
V·博尔达斯
D·格劳斯波塔
V·瓜格纳诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102596916A publication Critical patent/CN102596916A/zh
Application granted granted Critical
Publication of CN102596916B publication Critical patent/CN102596916B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080048756.3A 2009-10-30 2010-10-29 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物 Expired - Fee Related CN102596916B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09174619 2009-10-30
EP09174619.8 2009-10-30
PCT/EP2010/066435 WO2011051425A1 (en) 2009-10-30 2010-10-29 N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea

Publications (2)

Publication Number Publication Date
CN102596916A CN102596916A (zh) 2012-07-18
CN102596916B true CN102596916B (zh) 2015-06-17

Family

ID=41396002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080048756.3A Expired - Fee Related CN102596916B (zh) 2009-10-30 2010-10-29 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物

Country Status (7)

Country Link
US (3) US20120220600A1 (nl)
EP (1) EP2493864B1 (nl)
KR (1) KR20120101367A (nl)
CN (1) CN102596916B (nl)
ES (1) ES2524548T3 (nl)
IN (1) IN2012DN03180A (nl)
WO (1) WO2011051425A1 (nl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
AU2013241664B2 (en) * 2012-03-30 2016-05-19 Novartis Ag FGFR inhibitor for use in the treatment of hypophosphatemic disorders
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
RS56924B9 (sr) 2013-04-19 2019-09-30 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
SG11201602183QA (en) 2013-10-25 2016-05-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CA2956270C (en) 2014-08-18 2022-08-09 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
KR20170129757A (ko) * 2015-03-25 2017-11-27 노파르티스 아게 Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN111712245A (zh) 2018-03-28 2020-09-25 卫材R&D管理有限公司 用于肝细胞癌的治疗剂
EP3788047A2 (en) 2018-05-04 2021-03-10 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CN113185510B (zh) * 2021-04-12 2022-05-13 南京海纳医药科技股份有限公司 一种阿伐曲泊帕杂质的制备方法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336237A (zh) * 2005-12-21 2008-12-31 诺瓦提斯公司 作为fgf抑制剂的嘧啶基芳基脲衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770600B2 (en) * 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336237A (zh) * 2005-12-21 2008-12-31 诺瓦提斯公司 作为fgf抑制剂的嘧啶基芳基脲衍生物

Also Published As

Publication number Publication date
EP2493864B1 (en) 2014-10-01
US20160102062A1 (en) 2016-04-14
KR20120101367A (ko) 2012-09-13
US20120220600A1 (en) 2012-08-30
ES2524548T3 (es) 2014-12-10
WO2011051425A1 (en) 2011-05-05
EP2493864A1 (en) 2012-09-05
US20140378468A1 (en) 2014-12-25
CN102596916A (zh) 2012-07-18
IN2012DN03180A (nl) 2015-09-25

Similar Documents

Publication Publication Date Title
CN102596916B (zh) 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物
EP3584239A1 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
EP3628665B1 (en) Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
EP2604610B1 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
PL189182B1 (pl) Pochodne chinazoliny, kompozycja farmaceutyczna zawierająca pochodną chinazoliny oraz zastosowanie pochodnej chinazoliny
TWI325321B (en) Combinations comprising a vegf receptor inhibitor
US10590109B2 (en) Heterocyclic compounds used as FGFR inhibitors
MXPA01002175A (es) Derivados de quinazolina como medicamentos.
CN101679313A (zh) 用于治疗癌症或过度增殖性疾病的axl激酶抑制剂
JP2012519732A (ja) Ｒｈｏキナーゼ阻害剤
CN103003250A (zh) 作为激酶p70s6k抑制剂的二环氮杂环甲酰胺
KR20120007523A (ko) 디아미노 헤테로환 카르복사미드 화합물
CN105263934A (zh) 作为bet抑制剂的吡唑并-吡咯烷-4-酮衍生物及其在治疗疾病中的用途
CN103228649A (zh) 喹唑啉甲酰胺氮杂环丁烷
US11147801B2 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
Zhu et al. Fragment-based modification of 2, 4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants
EP3778586A1 (en) Quinazoline compound serving as egfr triple mutation inhibitor and applications thereof
EP3615027B1 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
KR20100043294A (ko) 항암제로서 사용되는 시클로펜타[ｇ]퀴나졸린 화합물
CN110016026A (zh) 一类具有抗肿瘤活性的嘧啶并吡啶酮类化合物、制备方法和用途
JP2021506935A (ja) ピリミジン誘導体系キナーゼ阻害剤類
ZA200200333B (en) Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists.
CZ324199A3 (cs) Léčivo k zabránění růstu solidního tumoru u člověka a způsob jeho výroby
JP2003500476A (ja) アリール置換された窒素複素環を有する新規のカルボン酸誘導体、その製造およびエンドセリン受容体アンタゴニストとしてのその使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150617

Termination date: 20171029

CF01 Termination of patent right due to non-payment of annual fee